RT Journal Article
T1 Characteristics, treatments and 1-year prognosis of hospitalized and ambulatory heart failure patients with chronic obstructive pulmonary disease in the European Society of Cardiology Heart Failure Long-Term Registry.
A1 Canepa, Marco
A1 Straburzynska-Migaj, Ewa
A1 Drozdz, Jaroslaw
A1 Fernandez-Vivancos, Carla
A1 Pinilla, Jose Manuel Garcia
A1 Nyolczas, Noemi
A1 Temporelli, Pier Luigi
A1 Mebazaa, Alexandre
A1 Lainscak, Mitja
A1 Laroche, Cécile
A1 Maggioni, Aldo Pietro
A1 Piepoli, Massimo F
A1 Coats, Andrew J S
A1 Ferrari, Roberto
A1 Tavazzi, Luigi
A1 ESC-HFA Heart Failure Long-Term Registry Investigators, 
K1 Beta-blockers
K1 Chronic obstructive pulmonary disease
K1 Heart failure
K1 Hospitalization
K1 Mortality
K1 Registry
AB To describe the characteristics and assess the 1-year outcomes of hospitalized (HHF) and chronic (CHF) heart failure patients with chronic obstructive pulmonary disease (COPD) enrolled in a large European registry between May 2011 and April 2013. Overall, 1334/6920 (19.3%) HHF patients and 1322/9409 (14.1%) CHF patients were diagnosed with COPD. In both groups, patients with COPD were older, more frequently men, had a worse clinical presentation and a higher prevalence of co-morbidities. In HHF, the increase in the use of heart failure (HF) medications at hospital discharge was greater in non-COPD than in COPD for angiotensin-converting enzyme inhibitors (+13.7% vs. +7.2%), beta-blockers (+20.6% vs. +11.8%) and mineralocorticoid receptor antagonists (+20.9% vs. +17.3%), thus widening the gap in HF treatment already existing between the two groups at admission. In CHF patients, there was a similar increase in the use of these medications after enrollment visit in the two groups, leaving a significant difference of 8.2% for beta-blockers in favour of non-COPD patients (89.8% vs. 81.6%, P  COPD frequently coexists in HHF and CHF, worsens the clinical course of the disease, and significantly impacts its therapeutic management and prognosis. The matter should deserve greater attention from the cardiology community.
YR 2017
FD 2017-09-26
LK http://hdl.handle.net/10668/11611
UL http://hdl.handle.net/10668/11611
LA en
DS RISalud
RD Apr 9, 2025